Myeloma in the Real World: What ’s really happening?

Multiple myeloma (MM) is the second most common haematological malignancy and predominantly a disease of the elderly. In the last two decades a range of new therapeutic options have become available leading to improvements in patient outcomes including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach towards more active management including use of sequential therapies, with the goal to prolong progression-free and overall survival, while preserving organ function to enable delivery of further therapy at relapse.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research